Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACT-15: Peri- or Post-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma
NCT01150630Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- May 2010
- Primary completion
- Apr 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin, epirubicin, gemcitabine, capecitabine in pancreatic adenocarcinoma (PDAC), sponsored by IRCCS Ospedale San Raffaele. Started May 2010; status: completed.
02
Drugs
cisplatinepirubicingemcitabinecapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01150630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01150630.